Business Context and Reporting Period
This Form 8-K Current Report was filed by Keros Therapeutics, Inc. on August 28, 2024. The filing serves as a Regulation FD disclosure to announce upcoming investor relations activities rather than to report financial results or operational changes.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report contains no financial statements or quantitative financial data.
Material Changes
No material changes to the company's financial condition or operations are reported in this document. The filing solely discloses scheduled management presentations.
Guidance, Outlook, and Management Commentary
Management has scheduled the following fireside chat presentations for Jasbir Seehra, Chair and Chief Executive Officer:
- Morgan Stanley 22nd Annual Global Healthcare Conference: September 4, 2024, at 4:05 p.m. Eastern time.
- 2024 Wells Fargo Healthcare Conference: September 5, 2024, at 10:15 a.m. Eastern time.
- 2024 Cantor Global Healthcare Conference: September 19, 2024, at 8:35 a.m. Eastern time.
The press release detailing these events is included as Exhibit 99.1. The filing explicitly states that the information is furnished and not "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the content of the press release attached as Exhibit 99.1 for specific details on the upcoming presentations.
- Monitor the company's investor relations website for webcast links or transcripts following the scheduled conference dates.
- Review the most recent 10-Q or 10-K filing for actual financial performance data, as this 8-K contains none.